Cargando…
A novel orally active gonadotropin‐releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology
PURPOSE: To evaluate the efficacy of an oral gonadotropin‐releasing hormone antagonist (GnRH Ant), relugolix (R), for assisted reproductive technology (ART). METHODS: We enrolled women undergoing ART using a GnRH Ant for controlled ovarian stimulation. We compared R; 20 mg/day with cetrorelix acetat...
Autores principales: | Hamada, Michiko, Horikawa, Michiharu, Ensaka, Chie, Enomoto, Megumi, Ishii, Rena, Toriumi, Rena, Tachibana, Naoyuki, Taketani, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658872/ https://www.ncbi.nlm.nih.gov/pubmed/34938148 http://dx.doi.org/10.1002/rmb2.12424 |
Ejemplares similares
-
Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
por: Lv, Jialu, et al.
Publicado: (2020) -
Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015) -
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
por: Osuga, Yutaka, et al.
Publicado: (2021) -
Different anti‐Műllerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): Clues to better ART outcomes
por: Ishii, Rena, et al.
Publicado: (2019) -
The addition of dydrogesterone improves the outcomes of pregnant women with low progesterone levels when receiving vaginal progesterone alone as luteal support in HRT‐FET cycles
por: Toriumi, Rena, et al.
Publicado: (2023)